Article: OPTISON Featured at Echocardiography Scientific Forum; OPTISON Studied in Patients with Recent Myocardial Infarction.

Article: Molecular Biosystems Completes Myocardial Perfusion Phase 2 ...
Business Wire;  August 26, 1999 ;     700+ words ... ... perfusion Phase 2 studies of OPTISON and submitted the results ... In all of these studies OPTISON Myocardial Contrast Echocardiography ... including those with recent myocardial infarction undergoing pharmacologic ... two studies evaluating OPTISON with exercise stress echo ...

Article: Molecular Biosystems Reports Third Quarter Financial Results, ...
Business Wire;  January 21, 1999 ;     700+ words ... ... 3rd Quarter Highlights -- 37% growth in OPTISON end-user sales -- Clinical trials for OPTISON ahead of schedule in Japan -- MBI begins ... end-user demand for its flagship product, OPTISON(R), in the third fiscal quarter ended ...

Article: Abstracts to be Presented at EuroEcho 2 Will Focus on Ultrasound ...
PR Newswire;  December 9, 1998 ;     700+ words ... ... NYSE: MB) reported today that OPTISON*, the world's first and only commercially ... developments in echocardiography. (* OPTISON is a trademark of Mallinckrodt Inc.) Topics to be addressed in the OPTISON abstracts presented at the meeting ...

Article: OPTISON Featured Center-Stage at Echocardiography ...
Business Wire;  September 21, 1998 ;     700+ words ... ... NYSE:MB), Monday announced that OPTISON(R), the only commercially available ... the symposium was the clinical use of OPTISON in stress echocardiography procedures ... University (St. Louis, Mo.), in which OPTISON appeared to provide significant diagnostic ...

Article: MOLECULAR BIOSYSTEMS SLICES STAFF AS OPTISON SALES FALTER ...
BIOWORLD Today;  November 12, 1998 ;     700+ words ... ... than-predicted volume of sales of its Optison ultrasound contrast imaging agent. MBI ... Approved by the FDA this past January, Optison is used in diagnosing heart disease by ... confront an economic barrier. Use of Optison costs $110 for each administration ...

Article: Alliance Pharmaceutical Corp. Subsidiary Announces Amendment of ...
Business Wire;  August 6, 2001 ;     700+ words ... ... announced today the amendment of the Optison(R) Product Rights Agreement (OPRA ... Mallinckrodt, a unit of Tyco Healthcare. Optison, an intravenous ultrasound contrast agent ... a royalty of 5 percent of net sales of Optison in the U.S. and Europe for as long ...

Article: Molecular Biosystems and Mallinckrodt Report on Phase II ...
Business Wire;  June 11, 1998 ;     700+ words ... ... myocardial perfusion clinical trials for OPTISON(tm). Data from these studies support the companies' belief that OPTISON may be a useful contrast agent for ... blood flow within the heart muscle. OPTISON is not approved for the evaluation ...